Articles By RheumNow
Does Your Hospital Staff Include a Donald Trump?
By RheumNow
When Donald Trump announced that he was running for president last summer, most people didn't know quite what to think. Was this serious or some sort of publicity stunt? Would he be in the race for more than just a few weeks of intense media spotlight?
Read Article
Outpatient Surgery Safe for Total Hip
By RheumNow
ORLANDO -- Total hip replacement can be performed safely and effectively on an outpatient basis for healthy patients, a researcher reported here.
Read Article
Muscle Weakness Predicts Disability in Scleroderma
By RheumNow
Muscle weakness was independently associated with disability in patients with scleroderma, and as muscle weakness worsened, disability also increased, according to findings from a retrospective, nested, case control study.
Read Article
Calling a Doctor by His or Her First Name
By RheumNow
Romeo and Juliet, Act II, Scene II: "What's in a name? That which we call a rose by any other name would smell as sweet. So Romeo would, were he not Romeo call'd, retain that dear perfection which he owes without that title."
Read Article
RA Flares Common After Anti-TNF Withdrawal
By RheumNow
The risk of a flare increased by more than three-fold over 1 year when patients with longstanding rheumatoid arthritis (RA) in remission, or with stable low disease activity, stopped their anti-tumor necrosis factor (TNF) treatment, Dutch researchers reported.
Read Article
Relapse Common in ANCA-Associated Vasculitis
By RheumNow
Overall survival and survival free of end-stage renal disease (ESRD) have both improved significantly over time in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but the risk of relapse has not.
Read Article
GCA: Uptick in Severe Infections in First Year
By RheumNow
Patients with giant cell arteritis (GCA) had a higher rate of severe infections compared with the general population, a French study found.
Read Article
Biosimilar of Remicade Works in Ankylosing Spondylitis
By RheumNow
CT-P13, a biosimilar of infliximab (Remicade), demonstrated comparable and durable efficacy in the treatment of ankylosing spondylitis (AS), a multinational study found.
Read Article
Steroid Over-Prescribing Persists in RA
By RheumNow
Almost half of patients with rheumatoid arthritis (RA) in the UK receive glucocorticoids from primary care physicians, and of those who are prescribed glucocorticoids, more than half receive more than 10 mg a day.
Read Article
Game-Changers 2015: Refining Treatment in Arthritis
By RheumNow
Widening experience with JAK inhibition for rheumatoid arthritis (RA) and tapering medications among RA patients in remission, along with the success of secukinumab for psoriatic arthritis (PsA), were the most important advances in rheumatology in 2015, according to specialists responding toMedPa
Read Article
